Cantor Fitzgerald Issues Positive Forecast for VYGR Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities researchers at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a note issued to investors on Wednesday, March 12th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will earn ($2.03) per share for the year, up from their previous estimate of ($2.20). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share.

VYGR has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Wedbush restated an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday. Wells Fargo & Company set a $10.00 price objective on Voyager Therapeutics and gave the company an “overweight” rating in a research report on Wednesday. Finally, Canaccord Genuity Group decreased their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $14.86.

Voyager Therapeutics Price Performance

NASDAQ VYGR opened at $3.90 on Friday. The firm has a market cap of $213.04 million, a PE ratio of 5.49 and a beta of 0.99. Voyager Therapeutics has a one year low of $3.56 and a one year high of $10.66. The stock’s 50 day simple moving average is $4.83 and its 200 day simple moving average is $5.82.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). The business had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter last year, the company earned $1.25 earnings per share.

Institutional Trading of Voyager Therapeutics

Several hedge funds have recently added to or reduced their stakes in VYGR. Erste Asset Management GmbH acquired a new stake in Voyager Therapeutics during the 3rd quarter worth $6,192,000. Vestal Point Capital LP raised its stake in Voyager Therapeutics by 151.0% during the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock worth $6,974,000 after buying an additional 740,000 shares during the period. Farallon Capital Management LLC raised its stake in Voyager Therapeutics by 12.2% during the 4th quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock worth $14,576,000 after buying an additional 278,700 shares during the period. Dimensional Fund Advisors LP raised its stake in Voyager Therapeutics by 24.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company’s stock worth $7,828,000 after buying an additional 275,571 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Voyager Therapeutics during the 4th quarter worth $746,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Insider Activity

In related news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold a total of 10,778 shares of company stock valued at $58,548 in the last 90 days. 4.53% of the stock is owned by company insiders.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.